

Brihad Abhyankar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11364889/publications.pdf>

Version: 2024-02-01

9
papers

1,795
citations

1306789

7
h-index

1473754

9
g-index

9
all docs

9
docs citations

9
times ranked

1836
citing authors

#	ARTICLE	IF	CITATIONS
1	Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. <i>New England Journal of Medicine</i> , 2019, 381, 1215-1226.	13.9	457
2	Long-term Efficacy of Vedolizumab for Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2017, 11, jjw176.	0.6	141
3	Long-term Efficacy of Vedolizumab for Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2017, 11, jjw177.	0.6	140
4	Efficacy and Safety of Vedolizumab in Ulcerative Colitis and Crohn's Disease Patients Stratified by Age. <i>Advances in Therapy</i> , 2017, 34, 542-559.	1.3	72
5	The safety of vedolizumab for ulcerative colitis and Crohn's disease. <i>Gut</i> , 2017, 66, 839-851.	6.1	630
6	Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 229-239.e5.	2.4	164
7	An Overview of the Mechanism of Action of the Monoclonal Antibody Vedolizumab. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 1437-1444.	0.6	184
8	Corticosteroid Dose Reduction in Ulcerative Colitis Patients Treated With Vedolizumab During the GEMINI 1 Trial. <i>American Journal of Gastroenterology</i> , 2015, 110, S790.	0.2	3
9	Sa1123 Infusion-Related Reactions With Vedolizumab Treatment in Patients With UC or CD During the GEMINI 1 and GEMINI 2 Clinical Trials. <i>Gastroenterology</i> , 2015, 148, S-232-S-233.	0.6	4